Online inquiry

IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11635MR)

This product GTTS-WQ11635MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LAG3&PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002286.6; NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902; 5133
UniProt ID P18627; Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11635MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14055MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ12137MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ8056MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ7868MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ9412MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ3646MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ11063MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ6582MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW